Nakamori Shiro, Rowin Ethan J, Rodriguez Jennifer, Ngo Long H, Manning Warren J, Maron Martin, Nezafat Reza
Departments of Medicine (Cardiovascular Division) Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, Japan.
Hypertrophic Cardiomyopathy Center, Lahey Medical Center, Burlington, Massachusetts, USA; Tufts University School of Medicine, Boston, Massachusetts, USA.
J Cardiovasc Magn Reson. 2024;26(2):101072. doi: 10.1016/j.jocmr.2024.101072. Epub 2024 Aug 2.
The extent of late gadolinium enhancement (LGE) on cardiovascular magnetic resonance (CMR) in patients with hypertrophic cardiomyopathy (HCM) is associated with an increased risk of sudden cardiac death events. However, the clinical significance of age-specific longitudinal changes in LGE is not well characterized in HCM. We sought to assess whether the risk of LGE progression diverges between young to middle-aged (ages 20-59 years) and older (≥ 60) adults with HCM.
A total of 102 HCM patients (age <60 years; n=75, age ≥60 years; n=27) undergoing serial CMR studies from two tertiary medical centers were evaluated. The median time interval between initial and follow-up CMR scans was 3.7 years. LGE was semiautomatically quantified by measuring regions with signal intensity >6 SD above the nulled remote myocardium and manually adjusting a grayscale threshold.
LGE was identified at baseline in 61 of the 102 HCM patients (60%), occupying 4.8 ± 3.9% of the left ventricular (LV) mass. At the end of the follow-up period, 53 of the 61 patients (87%) demonstrated an increase in the extent of LGE to 7.7 ± 5.4%, and 8 patients had no change. In 5 patients (5%), LGE increased to extensive with >15% of the LV mass. The rate of LGE progression was 0.7 ± 1.0%/year, including 21 patients (21%) with particularly accelerated progression of ≥1%/year. The risk of LGE progression ≥1%/year was significantly higher in patients <60 years than those ≥ 60 years (25% vs. 7%, p=0.03). The odds of LGE progression ≥1%/year was almost 4 times greater for patients <60 years compared with those ≥ 60 years (odds ratio, 4.2; 95%CI, 1.1-27.9). Age <60 years and LGE extent ≥ 10% were significant baseline predictors for future LGE progression ≥1%/year, even after adjustment for other potential risk factors.
In HCM, progressive fibrosis occurs more frequently in young to middle-aged patients, underscoring the importance of repeating CMR to re-evaluate for potential LGE progression in this age group.
肥厚型心肌病(HCM)患者心血管磁共振成像(CMR)上的延迟钆增强(LGE)范围与心脏性猝死事件风险增加相关。然而,HCM中LGE随年龄的纵向变化的临床意义尚未得到充分描述。我们试图评估HCM患者中,年轻至中年(20 - 59岁)和老年(≥60岁)成人之间LGE进展风险是否存在差异。
对来自两个三级医疗中心的102例接受系列CMR研究的HCM患者进行评估(年龄<60岁;n = 75,年龄≥60岁;n = 27)。首次和随访CMR扫描之间的中位时间间隔为3.7年。通过测量信号强度高于正常心肌6个标准差的区域并手动调整灰度阈值,对LGE进行半自动定量。
102例HCM患者中有61例(60%)在基线时发现LGE,占左心室(LV)质量的4.8±3.9%。随访期末,61例患者中有53例(87%)LGE范围增加至7.7±5.4%,8例无变化。5例患者(5%)LGE增加至广泛范围,占LV质量的>15%。LGE进展率为0.7±1.0%/年,其中21例患者(21%)进展特别加速,≥1%/年。年龄<60岁患者LGE进展≥1%/年的风险显著高于≥60岁患者(25%对7%,p = 0.03)。年龄<60岁患者LGE进展≥1%/年的几率几乎是≥60岁患者的4倍(优势比,4.2;95%CI,1.1 - 27.9)。即使在调整其他潜在风险因素后,年龄<60岁和LGE范围≥10%仍是未来LGE进展≥1%/年的显著基线预测因素。
在HCM中,年轻至中年患者中进行性纤维化更常见,这突出了在该年龄组重复CMR以重新评估潜在LGE进展的重要性。